An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis

Trial Profile

An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Abatacept (Primary)
  • Indications Juvenile rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 11 Nov 2015 Interim results (n = 146) presented at the 79th American College of Rheumatology and the 50th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 22 Feb 2015 Planned End Date changed from 1 Jun 2029 to 1 Dec 2029 as reported by ClinicalTrials.gov record.
    • 22 Feb 2015 Planned primary completion date changed from 1 Jun 2029 to 1 Dec 2029 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top